세계의 핵의학 시장 보고서(2025년)
Nuclear Medicine Global Market Report 2025
상품코드 : 1821586
리서치사 : The Business Research Company
발행일 : On Demand Report
페이지 정보 : 영문 250 Pages
 라이선스 & 가격 (부가세 별도)
US $ 4,490 ₩ 6,482,000
PDF (Single User License) help
PDF 보고서를 1명만 이용할 수 있는 라이선스입니다. 인쇄 가능하며 인쇄물의 이용 범위는 PDF 이용 범위와 동일합니다.
US $ 6,490 ₩ 9,370,000
PDF (Site License) help
PDF 보고서를 동일 사업장의 모든 분이 이용할 수 있는 라이선스입니다. 인쇄 가능하며 인쇄물의 이용 범위는 PDF 이용 범위와 동일합니다.
US $ 8,490 ₩ 12,257,000
PDF (Enterprise License) help
PDF 보고서를 동일 기업의 모든 분이 이용할 수 있는 라이선스입니다. 인쇄 가능하며 인쇄물의 이용 범위는 PDF 이용 범위와 동일합니다.


ㅁ Add-on 가능: 고객의 요청에 따라 일정한 범위 내에서 Customization이 가능합니다. 자세한 사항은 문의해 주시기 바랍니다.
ㅁ 보고서에 따라 최신 정보로 업데이트하여 보내드립니다. 배송기일은 문의해 주시기 바랍니다.

한글목차

핵의학 시장의 규모는 향후 수년간 급성장할 것으로 전망됩니다. 2029년에는 CAGR 11.3%로 156억 4,000만 달러로 성장할 전망입니다. 예측기간의 성장은 개별화 의료, 종양학 및 신경학 연구, 지속 가능한 진료, 연구개발, 원격의료서비스에 기인할 것으로 예상됩니다. 예측기간의 주요 동향은 방사선 면역요법, 하이브리드 이미징, 인공지능(AI), 신규 방사성 의약품 및 영상 진단의 진보를 포함합니다.

향후 5년간의 예측 성장률 11.3%는 과거 예측에서 0.2% 감소한 수치입니다. 이러한 성장세 둔화는 주로 미국과 다른 국가 간의 관세의 영향 때문입니다. 무역 마찰은 네덜란드와 캐나다에서 개발된 루테튬 177과 PET/CT 영상 진단제의 가격을 급등시켜 암 진단 지연과 방사선과 지출 증가를 초래함으로써 미국 내 테라노스틱스의 채용을 저해할 가능성이 있습니다. 또한 상호관세와 무역의 긴장과 한계 증가로 인한 세계 경제와 무역에 대한 악영향으로 인해 그 영향이 더욱 광범위해질 것으로 보입니다.

핵의학 시장의 성장은 심혈관질환(CVD)과 암의 빈도와 유병률 증가에 의해 촉진될 것으로 예측됩니다. 심혈관 질환에는 다양한 심장과 혈관장애가 포함되며, 암에는 통제 불가능한 세포 증식과 다른 신체 부위로의 전이가 포함됩니다. 핵의학 중에서도 특히 심장 핵의학 영상 진단 및 치료는 CVD의 신속한 진단 및 암 치료에 중요한 역할을 하며, 종종 수술 및 화학요법과 같은 다른 치료법과 병용됩니다. 2023년 1월 미국 암협회(American Cancer Society Inc.)가 제시한 바와 같이 미국의 신규 암 환자 수는 2022년 191만 8,030명에서 195만 8,310명으로 증가한 것으로 나타났으며, 이는 핵의학에 대한 수요 증가를 뒷받침하고 있습니다.

목차

제1장 주요 요약

제2장 시장 특징

제3장 시장 동향과 전략

제4장 시장 : 금리, 인플레이션, 지정학, 무역전쟁과 관세, 그리고 코로나 및 회복이 시장에 미치는 영향을 포함한 거시경제 시나리오

제5장 세계의 성장 분석과 전략 분석 프레임워크

제6장 시장 세분화

제7장 지역별/국가별 분석

제8장 아시아태평양 시장

제9장 중국 시장

제10장 인도 시장

제11장 일본 시장

제12장 호주 시장

제13장 인도네시아 시장

제14장 한국 시장

제15장 서유럽 시장

제16장 영국 시장

제17장 독일 시장

제18장 프랑스 시장

제19장 이탈리아 시장

제20장 스페인 시장

제21장 동유럽 시장

제22장 러시아 시장

제23장 북미 시장

제24장 미국 시장

제25장 캐나다 시장

제26장 남미 시장

제27장 브라질 시장

제28장 중동 시장

제29장 아프리카 시장

제30장 경쟁 구도와 기업 프로파일

제31장 기타 주요 기업 및 혁신 기업

제32장 세계 시장 경쟁 벤치마킹과 대시보드

제33장 주요 인수합병(M&A)

제34장 최근 시장 동향

제35장 시장의 잠재력이 높은 국가, 부문, 전략

제36장 부록

CSM
영문 목차

영문목차

Nuclear medicine is a specialized field of radiology that utilizes radioactive materials inside the body to examine and assess the overall health condition of a patient.

The main types of nuclear medicine procedures can be categorized as diagnostic and therapeutic. Diagnostic nuclear medicine involves examinations to identify specific areas of strength and weakness, helping in the diagnosis of conditions, diseases, or illnesses. Applications of nuclear medicine include cardiology, lymphoma, thyroid disorders, neurology, oncology, and various other medical fields. The end-users of nuclear medicine services typically include hospitals and clinics, diagnostic centers, and other medical facilities.

Note that the outlook for this market is being affected by rapid changes in trade relations and tariffs globally. The report will be updated prior to delivery to reflect the latest status, including revised forecasts and quantified impact analysis. The report's Recommendations and Conclusions sections will be updated to give strategies for entities dealing with the fast-moving international environment.

The sharp rise in U.S. tariffs and the resulting trade tensions in spring 2025 are having a significant impact on the healthcare sector, especially in the supply of essential medical devices, diagnostic equipment, and pharmaceuticals. Hospitals and healthcare providers are grappling with higher costs for imported surgical tools, imaging systems, and consumables like syringes and catheters, many of which have limited domestic substitutes. These escalating expenses are putting pressure on healthcare budgets, prompting some providers to delay equipment upgrades or pass increased costs on to patients. Furthermore, tariffs on raw materials and components are disrupting the manufacturing of vital drugs and devices, leading to supply chain delays. In response, the industry is adopting diversified sourcing strategies, expanding local production where feasible, and pushing for tariff exemptions on critical medical products.

The nuclear medicine market research report is one of a series of new reports from The Business Research Company that provides nuclear medicine market statistics, including nuclear medicine industry global market size, regional shares, competitors with a nuclear medicine market share, detailed nuclear medicine market segments, market trends and opportunities, and any further data you may need to thrive in the nuclear medicine industry. This nuclear medicine market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenarios of the industry.

The nuclear medicine market size has grown rapidly in recent years. It will grow from $8.93 billion in 2024 to $10.18 billion in 2025 at a compound annual growth rate (CAGR) of 14.0%. The growth in the historic period can be attributed to aging population, cancer diagnosis and staging, cardiology applications, neurological disorders, regulatory approvals.

The nuclear medicine market size is expected to see rapid growth in the next few years. It will grow to $15.64 billion in 2029 at a compound annual growth rate (CAGR) of 11.3%. The growth in the forecast period can be attributed to personalized medicine, oncology and neurology research, sustainable practices, research and development, telemedicine services. Major trends in the forecast period include radioimmunotherapy, hybrid imaging, artificial intelligence (AI), emerging radiopharmaceuticals, diagnostic imaging advancements.

The forecast of 11.3% growth over the next five years reflects a slight reduction of 0.2% from the previous projection. This reduction is primarily due to the impact of tariffs between the US and other countries. Trade tensions could hinder U.S. adoption of theranostics by inflating prices of lutetium-177 and PET/CT imaging agents developed in the Netherlands and Canada, resulting in delayed cancer diagnostics and higher radiology department expenditures. The effect will also be felt more widely due to reciprocal tariffs and the negative effect on the global economy and trade due to increased trade tensions and restrictions.

The growth of the nuclear medicine market is anticipated to be propelled by the increasing frequency and prevalence of cardiovascular diseases (CVD) and cancer. Cardiovascular diseases encompass various heart and blood vessel disorders, while cancer involves uncontrolled cell growth and spread to other body parts. Nuclear medicine, particularly nuclear cardiac imaging and therapy, plays a crucial role in the prompt diagnosis of CVDs and the treatment of cancer, often used in conjunction with other therapeutic options like surgery and chemotherapy. As indicated by the American Cancer Society Inc. in January 2023, the expected rise in new cancer cases in the US to 1,958,310 from 1,918,030 in 2022 underscores the growing demand for nuclear medicine.

The growing prevalence of chronic diseases is anticipated to drive the growth of the nuclear medicine market in the future. Chronic diseases are illnesses that persist for three months or longer and may worsen over time. This rise in chronic conditions creates a demand for accurate and timely diagnostics, personalized treatment, and effective monitoring. Nuclear medicine provides advanced imaging techniques and therapeutic applications, making it an essential aspect of managing chronic diseases. For example, in January 2023, the National Center for Biotechnology Information (NCBI), a US-based National Library of Medicine, projected that there would be 142.66 million individuals with chronic diseases globally by 2050, up from 71.522 million in 2020. Consequently, the increasing prevalence of chronic diseases is fueling the growth of the nuclear medicine market.

Major companies in the nuclear medicine market are concentrating on creating innovative solutions, such as nuclear medicine cyclotrons, to enhance the production of radiopharmaceuticals and improve diagnostic imaging capabilities. Nuclear medicine cyclotrons are specialized particle accelerators that generate radioactive isotopes for medical imaging and therapy by directing high-energy particles at target materials, facilitating the synthesis of radiopharmaceuticals used in procedures like positron emission tomography (PET). For example, in January 2024, GE Healthcare China, a US-based medical technology company, launched its first batch of cyclotrons on December 1, 2023, at the Chengdu Tianfu International Bio-Town. These advanced particle accelerators play a crucial role in nuclear medicine, enabling the production of medical isotopes used in molecular imaging and therapeutic applications. This initiative aims to establish a comprehensive ecosystem for nuclear medicine, thereby enhancing capabilities in early disease detection and personalized treatment.

Leading companies in the nuclear medicine market are investing in the development of new medical imaging devices and scanners to gain a competitive advantage. Siemens Healthineers, a Germany-based healthcare company, launched the Symbia Pro.specta SPECT/CT scanner in June 2022, featuring advanced single photon emission computed tomography and computed tomography (SPECT/CT) imaging capabilities. This system, equipped with low-dose CT with up to 64 slices, automated SPECT motion correction, and an intuitive workflow, enhances the quality and accessibility of SPECT/CT imaging.

In April 2022, Mediso Ltd., a Hungary-based nuclear medicine imaging equipment manufacturer, acquired Bartec Technologies Ltd. to bolster its market position in the UK and Ireland. The acquisition leverages Bartec Technologies' resources in nuclear medicine and molecular imaging equipment and accessories, contributing to Mediso's enhanced presence in the region.

Major companies operating in the nuclear medicine market include Bracco Imaging S.P.A., Lantheus Medical Imaging Inc., NTP Radioisotopes SOC Ltd., Eckert & Ziegler Group, Jubilant Pharma LLC, Australian Nuclear Science & Technology Organisation, Cardinal Health Inc., GE Healthcare Technologies Inc., Curium Pharma, Advanced Accelerator Applications USA Inc., Nordion Inc., The Institute for Radioelements, Eczacibasi-Monrol Nuclear Products Co., Siemens Healthineers AG, Cambridge Isotope Laboratories Inc., Bayer AG, Medtronic plc, Triad Isotopes Inc., FUJIFILM Holdings Corporation, Mallinckrodt Pharmaceuticals plc, PharmaLogic Holdings Corp., Institute of Isotopes Co. Ltd., Sinotau Pharmaceuticals Limited, Isotopia Molecular Imaging Limited, SHINE Medical Technologies Inc., Global Medical Solutions LLC, Charles River Analytics Inc., Touchlight Genetics Ltd., Numares B.V., Tech-X Corporation, Karyopharm Therapeutics Inc., JSC Isotope Inc., NorthStar Medical Radioisotopes LLC

North America was the largest region in the nuclear medicine market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in this nuclear medicine market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, the Middle East, and Africa.

The countries covered in the nuclear medicine market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA.

The nuclear medicine market consists of sales of bone density scanning, cardiac PET perfusion, cardiac PET sarcoid. Values in this market are 'factory gate' values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

Nuclear Medicine Global Market Report 2025 from The Business Research Company provides strategists, marketers and senior management with the critical information they need to assess the market.

This report focuses on nuclear medicine market which is experiencing strong growth. The report gives a guide to the trends which will be shaping the market over the next ten years and beyond.

Reasons to Purchase

Where is the largest and fastest growing market for nuclear medicine ? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward, including technological disruption, regulatory shifts, and changing consumer preferences? The nuclear medicine market global report from the Business Research Company answers all these questions and many more.

The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, competitive landscape, market shares, trends and strategies for this market. It traces the market's historic and forecast market growth by geography.

The forecasts are made after considering the major factors currently impacting the market. These include the technological advancements such as AI and automation, Russia-Ukraine war, trade tariffs (government-imposed import/export duties), elevated inflation and interest rates.

Scope

Table of Contents

1. Executive Summary

2. Nuclear Medicine Market Characteristics

3. Nuclear Medicine Market Trends And Strategies

4. Nuclear Medicine Market - Macro Economic Scenario Including The Impact Of Interest Rates, Inflation, Geopolitics, Trade Wars and Tariffs, And Covid And Recovery On The Market

5. Global Nuclear Medicine Growth Analysis And Strategic Analysis Framework

6. Nuclear Medicine Market Segmentation

7. Nuclear Medicine Market Regional And Country Analysis

8. Asia-Pacific Nuclear Medicine Market

9. China Nuclear Medicine Market

10. India Nuclear Medicine Market

11. Japan Nuclear Medicine Market

12. Australia Nuclear Medicine Market

13. Indonesia Nuclear Medicine Market

14. South Korea Nuclear Medicine Market

15. Western Europe Nuclear Medicine Market

16. UK Nuclear Medicine Market

17. Germany Nuclear Medicine Market

18. France Nuclear Medicine Market

19. Italy Nuclear Medicine Market

20. Spain Nuclear Medicine Market

21. Eastern Europe Nuclear Medicine Market

22. Russia Nuclear Medicine Market

23. North America Nuclear Medicine Market

24. USA Nuclear Medicine Market

25. Canada Nuclear Medicine Market

26. South America Nuclear Medicine Market

27. Brazil Nuclear Medicine Market

28. Middle East Nuclear Medicine Market

29. Africa Nuclear Medicine Market

30. Nuclear Medicine Market Competitive Landscape And Company Profiles

31. Nuclear Medicine Market Other Major And Innovative Companies

32. Global Nuclear Medicine Market Competitive Benchmarking And Dashboard

33. Key Mergers And Acquisitions In The Nuclear Medicine Market

34. Recent Developments In The Nuclear Medicine Market

35. Nuclear Medicine Market High Potential Countries, Segments and Strategies

36. Appendix

(주)글로벌인포메이션 02-2025-2992 kr-info@giikorea.co.kr
ⓒ Copyright Global Information, Inc. All rights reserved.
PC버전 보기